New drug launches in Europe have fallen sharply since the US introduced international reference pricing in May, according to market research firm GlobalData, echoing comments from industry executives and officials. Drug launches in EU markets fell by some 35% in the 10 months since Trump's executive order, compared with the previous 10 months, a GlobalData analysis found. France is among Europe's lowest-priced medicines markets, with prices around a third of the United States, he said. Some companies have even pulled their drugs from European markets. Launching drugs in Europe has stalled, he said, because it's like "playing a game of chess" wearing a "blindfold".

Source: The Telegraph March 31, 2026 08:16 UTC